A SWITCH TO BELATACEPT-BASED IMMUNOSUPPRESIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS FROM CALCINEURIN INHIBITORS (CNI) HAS A FAVOURABLE SAFETY PROFILE AND RESULTS IN IMPROVED RENAL FUNCTION: 12-MONTH RESULTS FROM A PHASE II STUDY

被引：0
|
作者：
Walker, R. G. [1 ]
Rostaing, L. [2 ]
Nainan, G. [3 ]
Rial M, Del C. [4 ]
Steinberg, S. [5 ]
Vincenti, F. [6 ]
Shi, R. [7 ]
Di Russo, G. [7 ]
Thomas, D. [7 ]
Xinos, C. [8 ]
Grinyo, J. [9 ]
机构：
[1] Royal Melbourne Hosp, Melbourne, Vic, Australia
[2] Univ Hosp, Toulouse, France
[3] Lakeshore Hosp, Cochin, Kerala, India
[4] Inst Nefrol, Buenos Aires, DF, Argentina
[5] Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA
[6] UCSF, San Francisco, CA USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Bristol Myers Squibb, Melbourne, Vic, Australia
[9] Univ Hosp Bellvitge, Barcelona, Spain
来源：
IMMUNOLOGY AND CELL BIOLOGY | 2011年 / 89卷 / 07期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：A3 / A3
页数：1
相关论文
共 50 条
  • [31] Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study.
    Silva, H. Tedesco
    Citterio, F.
    Henry, M.
    Srinivas, T. R.
    Watarai, Y.
    Steinberg, S.
    Basic-Jukic, N.
    Garcia, V. D.
    Mor, E.
    Peddi, V. R.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Pascual, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 358 - 359
  • [32] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR REGIMEN VERSUS MYCOPHENOLIC ACID WITH STANDARD CALCINEURIN REGIMEN IN ASIAN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: TWO-YEAR RESULTS FROM THE SUBGROUP ANALYSIS OF TRANSFORM STUDY
    Watarai, Yoshihiko
    Amante, Angel Joaquin
    Casasola, Concesa
    Kim, Myoung Soo
    Chang, Shen-Shin
    Han, Duck Jong
    Ingsathit, Atiporn
    Kee, Terence
    Kenmochi, Takashi
    Khullar, Dinesh
    Ruangkanchanasetr, Prajej
    Shu, Kuo-Hsiung
    Wong, Hin Seng
    Gawai, Apurva
    Hernandez-Gutierrez, Maria Pilar
    Danguilan, Romina
    TRANSPLANTATION, 2020, 104 (09) : S613 - S613
  • [33] OUTCOME ON RENAL FUNCTION, EFFICACY AND SAFETY IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS AFTER CONVERSION FROM CNI TO EVEROLIMUS-BASED REGIMEN: 5 YEAR DATA POST HOC ANALYSIS FROM THE ZEUS STUDY
    Lehner, F.
    Sommerer, C.
    Arns, W.
    Budde, K.
    Wuethrich, R.
    Reinke, P.
    Muehlfeld, A.
    Eisenberger, U.
    Stahl, R.
    Heller, K.
    Suwelack, B.
    Wolters, H.
    Hauser, I.
    Porstner, M.
    Witzke, O.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 242 - 243
  • [34] POST HOC SUBGROUP ANALYSIS FROM ZEUS: OUTCOME ON RENAL FUNCTION, EFFICACY AND SAFETY IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS AFTER CONVERSION FROM A CALCINEURIN INHIBITOR TO AN EVEROLIMUS BASED REGIMEN
    Lehner, F.
    Sommerer, C.
    Arns, W.
    Reinke, P.
    Eisenberger, U.
    Wuethrich, R. P.
    Pressmar, K.
    Porstner, M.
    May, C.
    Paulus, E. -M.
    Muehlfeld, A.
    Wolters, H. H.
    Witzke, O.
    Stahl, R. O.
    Budde, K.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 8 - 8
  • [35] Safety Profile of Valtoco® (diazepam nasal spray) in Patients With Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study
    Wheless, James
    Sperling, Michael
    Liow, Kore
    Segal, Eric
    Miller, Ian
    Hogan, R. Edward
    Tarquinio, Daniel
    Desai, Jay
    Dlugos, Dennis
    Biton, Victor
    Cascino, Gregory
    Carrazana, Enrique
    Rabinowicz, Adrian L.
    NEUROLOGY, 2021, 96 (15)
  • [36] Safety and Efficacy Profile of Everolimus With Reduced Tacrolimus in Living Donor Liver Transplant Recipients-12-month Results From the Pivotal H2307 Study
    Maluf, Daniel
    Jeng, Long-Bin
    Lee, Sung Gyu
    Soin, Arvinder S.
    Lee, Wei Chen
    Emond, Jean
    Lim, Kieron B.
    Lopez, Patricia M.
    Kochuparampil, Jossy
    Sips, Carole A.
    Kaneko, Shuhei
    Grant, David
    HEPATOLOGY, 2017, 66 : 901A - 901A
  • [37] Safety and Performance of the EnligHTN Renal Denervation System in Patients with Uncontrolled Hypertension and Chronic Kidney Disease: 12 Month Results from the EnligHTN II Study
    Lobo, Melvin
    Montarello, Joseph
    Saxena, Manish
    Jain, Ajay
    Walters, Darren
    Pincus, Matthew W.
    Worthley, Stephen G.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (15) : B313 - B314
  • [38] SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE: 12 MONTH RESULTS FROM THE ENLIGHTN II STUDY
    Lobo, M.
    Saxena, M.
    Jain, A.
    Walters, D.
    Pincus, M.
    Montarello, J.
    Worthley, S.
    JOURNAL OF HYPERTENSION, 2015, 33 : E363 - E363
  • [39] Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study.
    Oppenheimer, F.
    Legendre, C.
    Cruzado, J.
    Russ, G.
    Viklicky, O.
    Oberbauer, R.
    Garcia, V.
    Witzke, O.
    Kuypers, D.
    Danguilan, R.
    Bernhardt, P.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 258 - 258
  • [40] OUTCOME ON RENAL FUNCTION, EFFICACY AND SAFETY IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS AFTER CONVERSION FROM A CALCINEURIN INHIBITOR TO AN EVEROLIMUS BASED REGIMEN: A POST HOC SUBGROUP ANALYSIS OF ZEUS
    Lehner, F.
    Budde, K.
    Wuethrich, R. P.
    Witzke, O.
    Zeier, M.
    Hauser, I. A.
    Wolters, H. H.
    Suwelack, B.
    Heller, K.
    Reinke, P.
    Arns, W.
    Stahl, R.
    Muehlfeld, A.
    Eisenberger, U.
    Baeumer, D.
    Porstner, M.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2014, 27 : 24 - 24
12345